Training Programme in Translational Medicine and Therapeutics at the University of Cambridge: 'Novel therapeutics in multiple sclerosis and regulation of the immune system'. (360G-Wellcome-100535_Z_12_Z)
This project has two key goals: to investigate the role of IL7 and IL7R in the pathogenesis of multiple sclerosis and, in so doing, to educate a young physician about translational medicine. It is built upon the observations that IL7R is genetically associated with multiple sclerosis and that an antibody which antagonises IL7R ameliorated the animal model of multiple sclerosis by downregulating TH17 cells. The research question is: does antagonism of the IL7/IL7receptor pathway reduce disease activity in multiple sclerosis?The applicant will first investigate the in vitro consequences to lymphocyte biology of IL7R genotype; then explore the effect of this genotype on reconstitution of the lymphocyte repertoire therapeutic depletion. Then he will take part in a first-in-human anti-IL7R antibody trial in healthy individuals and people with multiple sclerosis. He will be involved in the design and execution of the clinical trial and the parallel laboratory studies.
£247,313 17 Sep 2012